Globus Medical (GMED) Receives Daily News Impact Rating of 0.13
News headlines about Globus Medical (NYSE:GMED) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Globus Medical earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news stories about the medical device company an impact score of 46.5860378797179 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Globus Medical (GMED) Updates FY18 Earnings Guidance (americanbankingnews.com)
- Analyst EPS Estimates Scan: Globus Medical, Inc. (GMED) – Theafricom (theafricom.com)
- Globus Medical (GMED) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Identify buying and selling opportunity on Globus Medical, Inc. (GMED) with Technical Facts – Wall Street Morning (wallstreetmorning.com)
- Medical Equipment Stocks’ Research Reports Released on Medtronic, Edwards Lifesciences, Globus Medical, and … – PR Newswire (press release) (prnewswire.com)
GMED has been the subject of a number of analyst reports. BidaskClub raised shares of Globus Medical from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Bank of America raised shares of Globus Medical from an “underperform” rating to a “neutral” rating in a report on Friday, November 10th. ValuEngine lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Friday, December 1st. BTIG Research reissued a “buy” rating and set a $37.00 price target on shares of Globus Medical in a research report on Thursday, November 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a research report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $38.86.
Shares of Globus Medical (NYSE GMED) traded up $1.26 during midday trading on Tuesday, hitting $45.69. 1,680,000 shares of the stock were exchanged, compared to its average volume of 690,616. The company has a market capitalization of $4,400.00, a PE ratio of 41.54, a price-to-earnings-growth ratio of 3.11 and a beta of 0.56. Globus Medical has a 52 week low of $24.70 and a 52 week high of $46.51.
Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Wednesday, November 8th. The medical device company reported $0.30 EPS for the quarter, meeting the consensus estimate of $0.30. The business had revenue of $151.74 million for the quarter, compared to analysts’ expectations of $150.73 million. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The firm’s revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.29 EPS. research analysts expect that Globus Medical will post 1.27 earnings per share for the current fiscal year.
In related news, Director David D. Davidar sold 55,383 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $40.66, for a total value of $2,251,872.78. Following the sale, the director now directly owns 752,236 shares of the company’s stock, valued at approximately $30,585,915.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider A Brett Murphy sold 51,449 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $35.00, for a total transaction of $1,800,715.00. Following the completion of the sale, the insider now directly owns 49,768 shares in the company, valued at $1,741,880. The disclosure for this sale can be found here. Insiders sold a total of 124,908 shares of company stock worth $4,747,975 over the last ninety days. 28.21% of the stock is currently owned by insiders.
About Globus Medical
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.